Merlin Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Merlin Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$847K	Buy	2,027 +45	+2%	+$19K	2.53%	13
2023 Q4	$806K	Sell	1,982 -30	-1%	-$11.1K	2.58%	6
2023 Q3	$700K	Sell	2,012 -29	-1%	-$10.1K	2.61%	6
2023 Q2	$718K	Sell	2,041 -251	-11%	-$84.6K	2.43%	12
2023 Q1	$722K	Sell	2,292 -46	-2%	-$13.8K	2.62%	8
2022 Q4	$675K	Sell	2,338 -106	-4%	-$32.3K	1.66%	23
2022 Q3	$708K	Sell	2,444 -369	-13%	-$106K	1.64%	13
2022 Q2	$793K	Sell	2,813 -221	-7%	-$59.2K	1.59%	15
2022 Q1	$792K	Sell	3,034 -947	-24%	-$225K	1.05%	25
2021 Q4	$874K	Buy	+3,981	New	+$774K	1.01%	30

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Merlin Capital's VRTX Position: Q1 2024 in Review

Merlin Capital increased its Vertex Pharmaceuticals (VRTX) stake by 2.3% in Q1 2024, buying an estimated $19K and bringing the position to 2,027 shares worth $847K. The position accounts for 2.53% of the portfolio, ranked #13.

Merlin Capital first reported a position in VRTX in Q4 2021 and has held it in 10 quarters since. The position peaked at $874K in Q4 2021. 1,493 funds tracked by Wall St. Rank hold VRTX as of Q1 2024.

Merlin Capital held 2,027 shares of Vertex Pharmaceuticals worth $847K as of Q1 2024.
Merlin Capital bought 45 Vertex Pharmaceuticals shares in Q1 2024, an estimated $19K.
Vertex Pharmaceuticals made up 2.53% of Merlin Capital's portfolio in Q1 2024, its #13 holding.
Merlin Capital first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 10 quarters since.
Merlin Capital's Vertex Pharmaceuticals position peaked at $874K in Q4 2021.
1,493 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2024.

Based on Merlin Capital's 13F filing for Q1 2024, filed 13 May 2024.